Bacterial Profile and Antimicrobial Susceptibility Patterns among Neonates with Suspected Sepsis at a Tertiary Hospital (ACSH) in Tigray, Northern Ethiopia: A Prospective Observational Study

Imagine a tiny, invisible battlefield happening inside a baby's body. The enemy? Tiny invaders called bacteria. The defenders? The baby's immune system and the medicine doctors give to help win the fight. Usually, doctors have a "standard playbook" of medicines they use right away when a baby looks sick, hoping to catch the enemy before it gets too strong. But here's the tricky part: bacteria are like sneaky spies. They can change their uniforms and learn how to dodge the most common weapons. This is called "antibiotic resistance." When bacteria become resistant, the old medicines stop working, and the fight gets much harder. This is a huge problem for newborns, whose bodies are still learning how to protect themselves. If the wrong medicine is used, or if the bacteria are too tough, the baby can get very sick. So, scientists and doctors need to know exactly which "spy" is causing the trouble and which "weapon" will actually stop it.

This is exactly what a team of researchers in Northern Ethiopia set out to do. They looked at a group of newborns in a big hospital who were suspected of having a serious infection called "sepsis." Think of sepsis as a fire that has spread from one room to the whole house; it's a life-threatening reaction to an infection that can happen very quickly in babies. The researchers wanted to find out two main things: first, what kind of bacteria were actually causing the fires, and second, which medicines would still work against them. They did this by taking tiny samples of blood from the babies and growing the bacteria in a lab to see what they were and how they reacted to different drugs.

The story they found was a mix of good news and a serious warning. Out of 526 babies who were suspected of having sepsis, about 1 in 4 (specifically 25.1%) actually had a confirmed bacterial infection. That's a lot of little battles happening at once. When they looked at the "bad guys," they found that most of them were a type of bacteria called "Gram-negative." Imagine these as the heavy tanks of the bacterial world. The most common tanks were Klebsiella and Enterobacter. There were also some "Gram-positive" bacteria, which are like the lighter infantry, with Coagulase-negative Staphylococci being the most common of those.

Now, here is where the plot gets tense. The researchers tested these bacteria against the medicines doctors usually reach for first. The results were alarming. The bacteria were almost completely immune to the standard "first-line" weapons. For example, 96.2% of the bacteria were resistant to a common drug called ampicillin, and 74.7% were resistant to another called ceftazidime. It's as if the enemy had learned to walk right through the front door of the hospital, ignoring the guards that used to stop them. This means the usual playbook the doctors were using might not be working anymore.

However, the researchers did find some weapons that were still effective. The bacteria were very sensitive to a drug called Amikacin (95.7% susceptibility) and another called Meropenem. It's like finding a secret weapon that the enemy hasn't learned to dodge yet. But there's a catch: these stronger weapons are often more expensive or harder to get, and the bacteria are also showing signs of becoming resistant to even more drugs, with about 43% of the infections being "multidrug-resistant" (meaning they can fight off many different types of medicine).

The study also looked at the outcomes of these battles. Sadly, 13.5% of the babies with confirmed sepsis did not survive. This is a heavy number, but the researchers also noted that many families had to leave the hospital early or move to other places because of the difficult situation in the region, which makes it hard to know the full story of how many babies recovered.

What does this all mean? The paper suggests that the bacteria causing infections in these newborns have changed. They are mostly Gram-negative, and they are very good at resisting the common medicines doctors have been using for a long time. The authors argue that doctors in this area need to update their "playbook" immediately. Instead of guessing which medicine to use, they should rely on these new findings to pick the right weapon—like Amikacin or Meropenem—so they can stop the infection before it spreads. The study acts like a map, showing that the terrain has changed, and the old paths no longer lead to safety. To keep the babies safe, the hospital needs to keep a close eye on these bacteria, test them often, and make sure the right medicines are ready to fight the new, tougher enemies.